Dupont Capital Management Corp Raises Holdings in AMAG Pharmaceuticals, Inc. (AMAG)

Dupont Capital Management Corp boosted its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 102.8% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 19,731 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,000 shares during the quarter. Dupont Capital Management Corp owned about 0.06% of AMAG Pharmaceuticals worth $364,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of AMAG. BlackRock Inc. lifted its position in AMAG Pharmaceuticals by 67,790.9% during the 1st quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after acquiring an additional 4,988,054 shares during the period. State Street Corp lifted its position in AMAG Pharmaceuticals by 75.2% during the 1st quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock worth $56,876,000 after acquiring an additional 1,082,366 shares during the period. Dimensional Fund Advisors LP lifted its position in AMAG Pharmaceuticals by 152.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock worth $23,129,000 after acquiring an additional 619,370 shares during the period. Goldman Sachs Group Inc. lifted its position in AMAG Pharmaceuticals by 162.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 607,980 shares of the specialty pharmaceutical company’s stock worth $13,710,000 after acquiring an additional 376,139 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its position in AMAG Pharmaceuticals by 175.1% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 525,989 shares of the specialty pharmaceutical company’s stock worth $9,679,000 after acquiring an additional 334,811 shares during the period.

A number of analysts have commented on the company. Piper Jaffray Companies assumed coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They set a “neutral” rating and a $18.00 price target for the company. Zacks Investment Research cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 26th. BidaskClub cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Morgan Stanley lowered their price target on AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd. Finally, Cowen and Company reissued a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $24.00.

AMAG Pharmaceuticals, Inc. (AMAG) opened at $14.05 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. AMAG Pharmaceuticals, Inc. has a 52 week low of $11.93 and a 52 week high of $36.83.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2017/11/13/dupont-capital-management-corp-raises-holdings-in-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply